Per- and polyfluoroalkyl substances (PFAS), often referred to as “forever chemicals,” are a large family of synthetic fluorinated compounds known for their exceptional chemical stability and resistance to degradation. Their persistence in the environment, together with growing evidence linking certain PFAS to adverse health and ecological effects, has placed these substances under increasing regulatory scrutiny worldwide.
Many medical devices rely on PFAS-based materials, particularly fluoropolymers, because they provide a unique combination of performance characteristics that are difficult to achieve with alternative materials. These properties include:
- Chemical resistance
- Low coefficient of friction
- Hydrophobicity
- Thermal stability
- Electrical insulation
- Biocompatibility
As a result, PFAS-containing materials are used in a wide range of medical technologies, including catheters, cardiovascular implants, surgical devices, diagnostic equipment, drug delivery systems, and medical device packaging.
The growing focus on PFAS regulation presents a complex challenge for the medical technology sector. While concerns regarding environmental persistence, waste management, and potential health impacts have led regulators to evaluate restrictions on PFAS use, many fluoropolymers remain critical components of life-sustaining and life-enhancing medical devices. Manufacturers must therefore balance device performance, patient safety, supply chain continuity, and evolving regulatory requirements.
 |
| Overview of PFAS use in medical devices, highlighting fluoropolymer materials, clinical applications, biological evaluation considerations, regulatory developments, manufacturing challenges, and emerging alternatives. |
What Are PFAS?
Per- and polyfluoroalkyl substances (PFAS) are a large and diverse group of synthetic fluorinated organic compounds that have been manufactured and used commercially since the mid-twentieth century. These substances are characterized by the presence of carbon–fluorine (C–F) bonds, one of the strongest chemical bonds found in organic chemistry. This exceptional bond strength contributes to the thermal stability, chemical resistance, and environmental persistence of many PFAS.
The Organisation for Economic Co-operation and Development (OECD) defines PFAS as fluorinated substances that contain at least one fully fluorinated methyl (-CF₃) or methylene (-CF₂-) carbon atom. Thousands of substances fall within this broad chemical class, including fluoropolymers, fluorinated surfactants, fluorinated processing aids, and specialty fluorinated lubricants.
PFAS have been used in numerous industrial and consumer applications because they provide unique performance characteristics, including:
- Resistance to heat and chemicals
- Water and oil repellency
- Low surface energy
- Low coefficient of friction
- Electrical insulation
- Long-term durability
These properties have led to widespread use of PFAS in cookware, textiles, food-contact materials, firefighting foams, electronics, aerospace systems, and medical technologies.
PFAS Used in Medical Devices
Medical devices predominantly utilize a subgroup of PFAS known as fluoropolymers. These high-molecular-weight materials are engineered polymers that exhibit exceptional biocompatibility, lubricity, chemical resistance, and long-term stability. Fluoropolymers are widely used in both implantable and non-implantable medical devices and have a long history of clinical use.
The following table summarizes several fluoropolymer materials commonly encountered in medical technologies.
| Material | Chemical Name | CAS Number | Typical Medical Applications |
|---|---|---|---|
| PTFE | Polytetrafluoroethylene | 9002-84-0 | Catheters, vascular grafts, guidewire liners, surgical implants |
| ePTFE | Expanded Polytetrafluoroethylene | Derived from PTFE | Vascular grafts, cardiovascular patches, hernia meshes |
| FEP | Fluorinated Ethylene Propylene | 25067-11-2 | Wire insulation, catheter components, tubing |
| PFA | Perfluoroalkoxy Polymer | 26655-00-5 | Fluid handling systems, diagnostic equipment, tubing |
| ETFE | Poly(ethylene-co-tetrafluoroethylene) | 25038-71-5 | Electrical insulation, implantable device components |
| PVDF | Polyvinylidene Fluoride | 24937-79-9 | Filtration systems, medical tubing, membranes |
| FKM | Fluoroelastomer Family | Various CAS Numbers | Seals, gaskets, O-rings, fluid handling systems |
| Substance | CAS Number | IUPAC Name | Common Use |
|---|---|---|---|
| PFOA | 335-67-1 | Perfluorooctanoic acid | Processing aid |
| PFOS | 1763-23-1 | Perfluorooctane sulfonic acid | Surfactant |
| PFHxS | 355-46-4 | Perfluorohexane sulfonic acid | Firefighting foams |
| PFNA | 375-95-1 | Perfluorononanoic acid | Industrial uses |
PFAS in Medical Technologies
PFAS-containing materials are used throughout the medical technology sector because they provide a combination of properties that are difficult to replicate with alternative materials. Applications include:
- Catheters and guidewire systems
- Pacemakers and cardiac rhythm management devices
- Cardiovascular implants and vascular grafts
- Surgical sutures and PTFE pledgets
- Hernia meshes
- Ophthalmic devices and contact lenses
- Medical tubing and fluid transfer systems
- Medical tapes and wound dressings
- Blood storage and collection systems
- Diagnostic instruments and analyzers
- Medical device packaging
PFAS may be present as a structural component of a medical device, as a surface coating, as part of a fluid-handling pathway, as a specialty lubricant, or as a processing aid used during manufacturing.
Fluoropolymers Versus Other PFAS
A critical distinction should be made between fluoropolymers commonly used in medical devices and certain lower-molecular-weight PFAS that have been associated with environmental contamination and human exposure concerns.
Fluoropolymers used in medical technologies generally:
- Possess very high molecular weights
- Exhibit limited mobility in biological systems
- Demonstrate excellent biocompatibility
- Have decades of clinical use history
- Provide long-term material stability
Because of these characteristics, fluoropolymers are often evaluated differently from other PFAS when considering patient exposure, toxicological risk, environmental persistence, and regulatory restrictions. Nevertheless, fluoropolymers remain part of the broader PFAS family and are increasingly included within ongoing discussions regarding PFAS regulation, lifecycle management, and sustainability.
Certain fluoropolymer materials are considered essential for many life-sustaining and life-enhancing medical devices because they provide a unique combination of biocompatibility, durability, electrical insulation, chemical resistance, and lubricity that is not easily replicated by currently available alternative materials.
Why Are Fluoropolymers Used in Medical Devices?
Medical devices are essential components of modern healthcare delivery, supporting the diagnosis, monitoring, treatment, and management of a wide range of medical conditions. Many of these devices rely on fluoropolymer materials because they possess a unique combination of physical, chemical, and biological properties that are difficult to achieve with alternative materials.
Fluoropolymers have been used in medical technologies for decades and are incorporated into numerous device categories, including cardiovascular implants, catheters, guidewires, drug delivery systems, diagnostic equipment, surgical devices, and implantable electronic systems. Their widespread adoption is largely attributable to their exceptional performance under demanding clinical conditions.
Currently, no single alternative material is capable of simultaneously replicating all of the critical properties provided by fluoropolymers across the broad range of medical device applications in which they are used.
Key Properties of Fluoropolymers in Medical Devices
Fluoropolymers are widely used in medical technologies because they provide a unique combination of mechanical, chemical, electrical, and biological properties that are difficult to achieve with alternative materials.
Lubricity (Low Friction Performance)
Fluoropolymers exhibit an exceptionally low coefficient of friction, enabling smooth movement through anatomical pathways and device delivery systems.
- Catheters
- Guidewires
- Introducer Sheaths
- Stent Delivery Systems
- Endoscopic Devices
- Minimally Invasive Surgical Instruments
Electrical Insulation
Many fluoropolymers possess excellent dielectric properties and electrical resistance, making them suitable for implantable and electrically powered medical devices.
- Pacemaker Leads
- ICD Leads
- Neurostimulation Systems
- Electrosurgical Equipment
- Diagnostic Instruments
Biostability
Biostability is the ability of a material to maintain structural integrity and performance during prolonged exposure to physiological environments.
- Hydrolysis
- Oxidation
- Chemical Degradation
- Enzymatic Attack
- Physiological Fluids
Chemical Resistance
Fluoropolymers resist a wide range of chemicals encountered during manufacturing, sterilization, storage, and clinical use.
- Fluid Handling Systems
- Drug Delivery Devices
- Diagnostic Analyzers
- Sterilizable Equipment
- Laboratory Instruments
Thermal Stability
Many fluoropolymers maintain physical and mechanical properties across a broad temperature range.
- Steam Sterilization
- Ethylene Oxide Sterilization
- Hydrogen Peroxide Sterilization
- Radiation Sterilization
Biocompatibility
Several fluoropolymers have decades of successful clinical use and are widely recognized for favorable biological performance.
- ISO 10993 Biological Evaluation
- Clinical Use History
- Implantable Device Applications
- Patient-Contacting Device Applications
Why Material Substitution Is Challenging
The growing regulatory focus on PFAS has increased interest in identifying alternative materials. However, replacing fluoropolymers is often technically challenging because alternative materials may replicate one or two desirable characteristics while failing to provide the complete combination of:
- Lubricity
- Biostability
- Chemical resistance
- Thermal stability
- Electrical insulation
- Biocompatibility
As a result, any proposed material substitution typically requires extensive design verification, validation, biological evaluation, risk assessment, and regulatory review before implementation in a medical device.
Why Are Concerns About These Chemicals in 2026?
Regulatory and scientific interest in PFAS has increased significantly in recent years as evidence has accumulated regarding the environmental persistence, bioaccumulation potential, and potential adverse health effects of certain PFAS substances. As a result, regulatory authorities worldwide are reassessing the use of PFAS across numerous industries, including the medical technology sector.
From a medical device perspective, the discussion is evolving beyond traditional material performance considerations and increasingly includes lifecycle impacts, chemical characterization, long-term exposure assessment, degradation products, and environmental sustainability.
Evolving Expectations for Biological Safety Evaluation
Recent updates to biological evaluation practices, including the publication of ISO 10993-1:2025, place continued emphasis on a risk-based approach to biological safety assessment throughout the medical device lifecycle. Particular attention is increasingly being given to:
- Chemical characterization of materials
- Extractables and leachables assessment
- Toxicological risk assessment
- Degradation products and their biological impact
- Long-term and cumulative exposure considerations
- Persistent, bioaccumulative, or substances of toxicological concern
- Lifecycle-based evaluation of patient exposure
For PFAS-containing materials, these considerations may require manufacturers to better understand potential sources of patient exposure and demonstrate that identified risks remain acceptable throughout the intended use of the device.
Bioaccumulation and ISO 10993-1:2025
One of the notable developments in ISO 10993-1:2025 is the explicit consideration of bioaccumulation within the biological evaluation process. Bioaccumulation refers to the gradual build-up of a substance within the body when the rate of absorption exceeds the rate at which the substance can be metabolized or eliminated.
Certain PFAS substances are known to be highly persistent and may remain in the human body for extended periods following repeated or prolonged exposure. Unlike many chemicals that are readily degraded or excreted, some PFAS can accumulate in blood, organs, and tissues over time. This characteristic has contributed significantly to global regulatory concern regarding PFAS.
The inclusion of bioaccumulation considerations within ISO 10993-1:2025 reflects a broader shift toward evaluating not only immediate biological effects but also the potential consequences of long-term exposure to persistent substances. Manufacturers are increasingly expected to assess whether device constituents, extractables, leachables, degradation products, or other chemical species could contribute to cumulative patient exposure over the intended duration of device use.
While many fluoropolymers used in medical devices differ substantially from lower-molecular-weight PFAS that have demonstrated bioaccumulative behavior, the persistence of PFAS as a chemical class has resulted in increased regulatory scrutiny of PFAS-containing materials throughout the product lifecycle.
Human Health Concerns Associated with Certain PFAS
A substantial body of scientific literature has examined the health effects associated with exposure to specific PFAS substances, particularly certain low-molecular-weight PFAS that have historically been used in industrial applications.
Studies involving exposed populations have reported associations with:
- Developmental effects affecting fetal growth and development
- Reduced immune response, including reduced vaccine response
- Thyroid disorders
- Elevated cholesterol levels
- Liver effects
- Kidney cancer
- Testicular cancer
According to the European Environment Agency (EEA), effects on the immune system appear among the most sensitive endpoints observed in human populations exposed to certain PFAS substances.
It is important to note that these findings are not necessarily representative of all PFAS materials and should not be directly extrapolated to all fluoropolymers used in medical devices, which often differ substantially in molecular structure, molecular weight, mobility, exposure pathways, and toxicological behavior.
Why Is This Relevant to Medical Devices?
The primary concern for medical device manufacturers is not simply whether a fluoropolymer is present in a device, but whether there is a realistic pathway for patient or environmental exposure to PFAS-related substances.
Potential areas of regulatory interest include:
- Manufacturing residues and processing aids
- Extractable and leachable substances
- Material degradation products
- Long-term implant exposure
- Repeated or cumulative patient exposure
- Waste management and disposal practices
- Environmental release during manufacturing
- End-of-life disposal and incineration
Consequently, regulatory authorities are increasingly evaluating PFAS from a lifecycle perspective, considering not only patient safety but also environmental persistence, bioaccumulation potential, and sustainability.
The Emerging Regulatory Challenge
The medical technology sector faces a complex challenge. Many fluoropolymers remain essential for the performance, reliability, and safety of critical medical devices, yet regulators are simultaneously seeking to reduce environmental releases of persistent PFAS substances.
As a result, manufacturers are expected to strengthen material characterization activities, improve supply-chain transparency, assess potential alternatives where feasible, evaluate bioaccumulation and long-term exposure risks where applicable, and demonstrate that the benefits of PFAS-containing materials continue to outweigh any identified risks throughout the product lifecycle.
Impact on Medical Device Manufacturers
The increasing regulatory scrutiny of PFAS is creating significant challenges for the medical technology sector. While many fluoropolymers remain essential for the performance, reliability, and safety of medical devices, manufacturers are facing growing pressure to understand PFAS use within their products, evaluate potential alternatives, and prepare for evolving regulatory requirements.
The impact extends far beyond material selection and affects product design, supply chains, regulatory compliance activities, biological safety evaluations, and long-term business continuity planning.
1. Supply Chain Vulnerability
One of the most immediate concerns is supply chain disruption.
Many medical device manufacturers depend on specialized fluoropolymers, fluorinated coatings, fluorinated processing aids, seals, tubing, and other PFAS-containing materials supplied by a relatively limited number of manufacturers worldwide. Regulatory restrictions, reduced production capacity, or supplier withdrawal from PFAS manufacturing may affect the long-term availability of these materials.
A notable example is 3M's 2022 announcement that it would exit PFAS manufacturing and discontinue PFAS use across its product portfolio. The company completed its exit from PFAS manufacturing at the end of 2025.
For medical device manufacturers, the loss of major suppliers may require:
- Supplier requalification
- Identification of alternative material sources
- Design modifications
- Additional verification and validation activities
- Regulatory submissions associated with material changes
2. Increased Material Characterization Requirements
Regulators increasingly expect manufacturers to possess a detailed understanding of the chemical composition of materials used within their devices.
This includes:
- Material inventories
- PFAS identification programs
- Chemical characterization activities
- Extractables and leachables assessments
- Toxicological risk assessments
- Evaluation of degradation products
Manufacturers may need to obtain significantly more information from suppliers regarding PFAS content, processing aids, and residual substances than was historically required.
3. Design Change and Revalidation Burden
Where PFAS-containing materials are replaced, even seemingly minor material changes can trigger extensive engineering and regulatory activities.
Potential requirements may include:
- Design verification testing
- Performance testing
- Biocompatibility assessment
- Sterilization validation
- Shelf-life evaluation
- Packaging validation
- Clinical assessment updates
- Risk management file updates
For implantable and long-term patient-contacting devices, demonstrating equivalence between the original and replacement material may require substantial evidence.
4. Regulatory Compliance Challenges
Medical device manufacturers must navigate multiple regulatory frameworks simultaneously.
Potentially affected areas include:
- EU REACH requirements
- EU MDR and IVDR requirements
- ISO 10993 biological evaluation
- Chemical characterization standards
- Environmental reporting obligations
- National PFAS reporting requirements
The challenge is compounded by the fact that environmental regulations may evolve independently of medical device regulations, creating complex compliance obligations throughout the product lifecycle.
5. Patient Access and Technology Availability
Industry organizations have expressed concern that rapid restrictions on PFAS could affect the availability of certain medical technologies where technically and clinically suitable alternatives do not yet exist.
In its position on the proposed EU PFAS restriction, MedTech Europe stated that the unavailability of suitable alternatives could affect the availability of some medical technologies and called for transition periods that allow manufacturers sufficient time to identify, validate, and obtain regulatory approval for replacement materials.
The Path Forward
Rather than a simple material substitution exercise, PFAS management is becoming a strategic issue for the medical technology sector.
Manufacturers are increasingly expected to:
- Establish PFAS inventories
- Improve supply-chain transparency
- Strengthen chemical characterization programs
- Evaluate alternative materials where feasible
- Assess long-term supply continuity risks
- Incorporate PFAS considerations into lifecycle risk management
The challenge for the industry is to balance environmental sustainability objectives with the continued availability, safety, and performance of critical medical technologies that currently rely on fluoropolymer-based materials.
PFAS Material Substitution Challenges in Medical Devices
Fluoropolymers and other PFAS-based materials play critical roles in numerous medical technologies due to their unique combination of lubricity, biostability, chemical resistance, thermal stability, electrical insulation, and biocompatibility. As regulatory scrutiny of PFAS increases globally, manufacturers are evaluating alternative materials where technically feasible. However, the availability of a substitute does not necessarily imply equivalence, and replacement often requires extensive verification, validation, biological evaluation, and regulatory assessment.
| Material | PFAS Family | Typical Medical Applications | Critical Performance Attributes | Potential Alternatives | Replacement Difficulty |
|---|---|---|---|---|---|
| PTFE | Fluoropolymer | Catheters, guidewire liners, vascular grafts, surgical implants, PTFE sutures and pledgets | Extremely low friction, chemical resistance, biostability, biocompatibility | UHMWPE, PEEK, Polyimide, Silicone coatings | Very High |
| ePTFE | Fluoropolymer | Vascular grafts, cardiovascular patches, hernia meshes, implantable membranes | Porosity control, tissue integration, flexibility, long-term implant stability | PET (Dacron), Polyurethane, Biological graft materials | Very High |
| FEP | Fluoropolymer | Catheter components, medical tubing, wire insulation, heat-shrink applications | Chemical resistance, transparency, electrical insulation, thermal stability | Polyurethane, Polyethylene, Pebax®, Polyolefins | High |
| PFA | Fluoropolymer | High-purity fluid pathways, bioprocessing systems, diagnostic analyzers | Ultra-high chemical resistance, purity, thermal stability | PEEK, Polypropylene, HDPE, Polyethersulfone | High |
| ETFE | Fluoropolymer | Implantable device insulation, electrical wiring, diagnostic equipment | Mechanical strength, radiation resistance, electrical insulation | Polyimide, PEEK, Silicone, Polyurethane | Moderate–High |
| PVDF | Fluoropolymer | Filtration systems, membranes, medical tubing, bioprocessing equipment | Chemical resistance, mechanical strength, piezoelectric properties | PES, PSU, Polypropylene, Polyethersulfone | Moderate |
| FKM | Fluoroelastomer | O-rings, seals, gaskets, pumps, fluid handling systems | Chemical resistance, temperature resistance, sealing performance | EPDM, Silicone Rubber, HNBR, TPE | Moderate |
| PFPE Lubricants | Specialty PFAS | Catheter coatings, device assembly, precision mechanisms | Lubricity, chemical inertness, thermal stability | Silicone lubricants, Ester-based lubricants, Synthetic hydrocarbons | Moderate–High |
Key Takeaway:
PFAS and fluoropolymer-based materials have played a critical role in the development of modern medical technologies for decades. Their unique combination of lubricity, biostability, chemical resistance, thermal stability, electrical insulation, and biocompatibility has enabled the safe and effective performance of numerous medical devices, including catheters, cardiovascular implants, diagnostic systems, and implantable electronic devices.
At the same time, growing scientific evidence regarding the persistence, bioaccumulation potential, and environmental impact of certain PFAS substances has prompted increased regulatory scrutiny worldwide. Recent developments, including evolving PFAS restrictions and enhanced biological evaluation expectations under ISO 10993-1:2025, are encouraging manufacturers to more thoroughly assess material composition, exposure pathways, degradation products, and lifecycle impacts.
For the medical technology sector, the challenge extends beyond regulatory compliance. Manufacturers must balance environmental sustainability objectives with the continued availability, safety, and performance of critical medical devices that currently depend on fluoropolymer materials. While alternative materials are being explored, suitable substitutes are not yet available for many applications.
